[Midocalm in complex therapy of chronic low back pain syndrome].
The aim of the study was to determine whether application of midocalm is appropriate in patients with chronic low back pain (LBP) from the point of view of quality of life (QL), efficacy and tolerance. The subjects were 50 patients with chronic LBP associated with spinal osteochondrosis, who underwent clinical examination and were questioned using four QL questionnaires: Health Assessment Questionnaire (HAQ), Womac osteoarthritis index Womac osteoarthritis index, Oswestry Low Back Pain Disability Questionnaire, and The 36-Item Short-Form Health Survey (SF-36). The subjects were divided into two groups. The 25 patients of Group I were administered nise in a dose of 100 mg twice a day during 10 days, the 25 patients of Group II--nise in a dose of 100 mg twice a day plus midocalm in a dose of 150 mg per day during the first two days and 450 mg per day from the third day through the tenth day. The study showed high efficacy of midocalm in complex therapy of patients with chronic LBP, as well as low rate of adverse reactions and high treatment tolerance. QL of the patients improved. Combining midocalm therapy with nise allows quicker positive effect in patients with chronic LBP and lowers need for long application of non-steroid antiinflammatory drugs.
Chernysheva
T V
TV
Bagirova
G G
GG
D015502:Absorptiometry, Photon; D001416:Back Pain / Q000209:etiology / Q000503:physiopathology / Q000628:therapy*; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009125:Muscle Relaxants, Central / Q000627:therapeutic use*; D010007:Osteochondritis / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy; D010147:Pain Measurement; D026741:Physical Therapy Modalities; D011788:Quality of Life; D012720:Severity of Illness Index; D013577:Syndrome; D014049:Tolperisone / Q000627:therapeutic use*; D016896:Treatment Outcome
D009125:Muscle Relaxants, Central; D014049:Tolperisone